{
  "patent_number": "US 12083190",
  "country": "US",
  "title": "How an mRNA Vaccine Teaches Your Body to Fight Rabies",
  "original_title": "Rabies vaccine",
  "summary": "This patent describes a method for creating an immune response against the rabies virus by injecting a specific messenger RNA molecule that instructs cells to produce a key rabies protein.",
  "what_it_does": "This patent details a method to stimulate a protective immune response against the rabies virus. It involves administering a pharmaceutical composition containing a purified mRNA molecule (Claim 1). This mRNA molecule is engineered with specific parts: a 5′ Cap, an Open Reading Frame (ORF) that codes for the Rabies virus glycoprotein (RAV-G), and a Poly(A) sequence. The ORF is very similar (at least 95% identical) to a specific genetic sequence (SEQ ID NO: 24) for the RAV-G protein. The composition is delivered by injection, typically into a muscle or just under the skin (Claim 2, 3). For example, a person would receive an intramuscular shot containing this specially designed mRNA, and their cells would then temporarily produce the RAV-G protein, triggering an immune response without causing disease.",
  "what_it_does_not_cover": [
    "Does not cover rabies vaccines that use inactivated virus or live-attenuated virus, as it specifically claims a purified mRNA molecule.",
    "Does not cover mRNA vaccines for rabies that do not encode the Rabies virus glycoprotein (RAV-G) or a sequence at least 95% identical to SEQ ID NO: 24.",
    "Does not cover methods of administration other than injection, such as oral vaccines or nasal sprays.",
    "Does not cover mRNA compositions that lack a 5' Cap or a Poly(A) sequence, which are essential elements of the claimed mRNA molecule.",
    "Does not cover mRNA vaccines for rabies that are not formulated with a cationic or polycationic compound if administered intramuscularly (Claim 15)."
  ],
  "filed": "2022-05-17",
  "granted": "2024-09-10",
  "expires": "2042-05-17",
  "status": "active",
  "holder": "Curevac SE",
  "holder_url": "https://patentbrief.org/company/curevac-se",
  "inventors": [
    {
      "name": "Margit Schnee",
      "url": "https://patentbrief.org/inventor/margit-schnee"
    },
    {
      "name": "Thomas Kramps",
      "url": "https://patentbrief.org/inventor/thomas-kramps"
    },
    {
      "name": "Benjamin Petsch",
      "url": "https://patentbrief.org/inventor/benjamin-petsch"
    },
    {
      "name": "Lothar Stitz",
      "url": "https://patentbrief.org/inventor/lothar-stitz"
    }
  ],
  "times_cited": 0,
  "tags": [
    "biotech",
    "pharmaceutical",
    "telecommunications"
  ],
  "abstract": "The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.",
  "url": "https://patentbrief.org/patent/us/12083190/rabies-vaccine",
  "markdown_url": "https://patentbrief.org/patent/us/12083190/rabies-vaccine/md",
  "google_patents_url": "https://patents.google.com/patent/US12083190",
  "relatedPatents": [
    {
      "patentNumber": "10702600",
      "countryCode": "US",
      "title": "How Moderna's mRNA Vaccine Technology Targets Betacoronaviruses",
      "url": "https://patentbrief.org/patent/us/10702600/betacoronavirus-mrna-vaccine"
    },
    {
      "patentNumber": "8278036",
      "countryCode": "US",
      "title": "How Modified RNA Tricks Cells Into Making Proteins Without Triggering Attacks",
      "url": "https://patentbrief.org/patent/us/8278036/rna-containing-modified-nucleosides-and-methods-of-use-thereof"
    },
    {
      "patentNumber": "20160166668",
      "countryCode": "US",
      "title": "How an mRNA Vaccine Targets Prostate Cancer with Six Antigens",
      "url": "https://patentbrief.org/patent/us/20160166668/composition-and-vaccine-for-treating-prostate-cancer"
    },
    {
      "patentNumber": "12048738",
      "countryCode": "US",
      "title": "Using mRNA to Teach the Body to Fight Prostate Cancer",
      "url": "https://patentbrief.org/patent/us/12048738/composition-for-treating-prostate-cancer-pca"
    },
    {
      "patentNumber": "20160168227",
      "countryCode": "US",
      "title": "How an mRNA Vaccine for Lung Cancer Teaches the Immune System to Fight",
      "url": "https://patentbrief.org/patent/us/20160168227/composition-and-vaccine-for-treating-lung-cancer"
    }
  ]
}